Previous Close | 0.4400 |
Open | 0.4350 |
Bid | 0.4200 x N/A |
Ask | 0.4350 x N/A |
Day's Range | 0.4350 - 0.4350 |
52 Week Range | 0.2200 - 1.2000 |
Volume | |
Avg. Volume | 45,222 |
Market Cap | 18.182M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.70 |
Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the "Offering") of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satell
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos proposes to raise gross proceeds of u